Clinical Trial Update: Trial of the Efficacy of Intravenous Immunoglobulin for Treating Women With Unexplained Secondary Recurrent Miscarriage [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating intravenous immunoglobulin for women with unexplained secondary recurrent miscarriage has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Miscarriage

Drugs mentioned

• Intravenous Immunoglobulin (IVIG)

Snippet

Sponsor: Rigshospitalet, Denmark | Conditions: Secondary Recurrent Miscarriage | Phase 3 | Status: COMPLETED